Clinical trials: FOLFOX
Colorectal Cancer
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
This is a non-randomized, open-label, Phase II trial investigating axitinib as a single-agent maintenance therapy following standard first-line FOLFOX/bevacizumab therapy for patients with mCRC.
- Trial name
- NCT01490866
- Testing
- Axitinib, Bevacizumab, 5-Fluorouracil
- Where
- 12 sites in United States
- Volunteers
- 70 people
- Sponsor
- SCRI Development Innovations, LLC
Colorectal Cancer (CRC)
Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer
The goal of this clinical trial is to learn if adding savolitinib to cetuximab plus FOLFOX chemotherapy works as a first-line treatment for patients with RAS/BRAF wild-type metastatic colorectal cancer, and to evaluate its…
- Trial name
- NCT07683403
- Testing
- Savolitinib plus cetuximab and FOLFOX chemotherapy, Cetuximab and FOLFOX chemotherapy
- Where
- 5 sites in China
- Volunteers
- 138 people
- Sponsor
- Fudan University
Rectal Cancer
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
This is a multicenter, prospective, randomized, stratified, controlled, open-label study comparing preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk…
- Trial name
- NCT04495088
- Testing
- mFOLFOX (neoadjuvant), XELOX (neoadjuvant), mFOLFOX (adjuvant)
- Where
- Germany
- Volunteers
- 215 people
- Sponsor
- Ralf Hofheinz
Advanced Cancers
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
The goal of this clinical research study is to find the highest tolerable doses of the combinations of lenalidomide and other drugs that can be given to patients with advanced cancer.
- Trial name
- NCT01183663
- Testing
- Lenalidomide, Bevacizumab, Sorafenib
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
Atezolizumab plus bevacizumab is the first-line treatment for patients with advanced hepatocellular carcinoma. However, the prognosis for high-risk hepatocellular carcinoma is still poor, with a median overall survival of 7.6…
- Trial name
- NCT05886465
- Testing
- Atezolizumab, Bevacizumab, HAIC with FOLFOX
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer
POF Versus FOLFOX Plus IP Paclitaxel in AGC
The aim of this study was to compare the efficacy and safety of intravenous or intraperitoneal paclitaxel plus FOLFOX as first-line treatment in AGC with peritoneal metastases, a phase II Clinical trial.
- Trial name
- NCT04155671
- Testing
- POF, FOLFOX plus PAC(ip)
- Volunteers
- 260 people
- Sponsor
- Fujian Cancer Hospital
Metastatic Pancreatic Cancer
Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer
The investigators are to evaluate the efficacy and safety of FOLFOX or FOLFIRI.3 combination chemotherapy as second-line salvage chemotherapy in patients with advanced pancreatic carcinoma.
- Trial name
- NCT00786006
- Testing
- FOLFIRI.3, FOLFOX
- Where
- South Korea
- Volunteers
- 61 people
- Sponsor
- Asan Medical Center
Colorectal Cancer
Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.
This is a randomized, double-blind, phase III clinical trial. The study aims to demonstrate that the treatment regimen of Enlituo® plus FOLFOX is equivalent to that of Erbitux® plus FOLFOX in participants with RAS/BRAF wild-type…
- Trial name
- NCT07595276
- Testing
- Enlituo®, Erbitux®
- Where
- China
- Volunteers
- 608 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Metastatic Colorectal Cancer
Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC
Bev improves the efficacy of first-line chemotherapy in unresectable mCRC. In the phase III TRIBE trial upfront FOLFOXIRI plus bev provided a significant advantage in terms of PFS and RR compared to FOLFIRI plus bev.
- Trial name
- TRIBE2 (NCT02339116)
- Testing
- fluoruracil, Oxaliplatin, Irinotecan
- Where
- Italy
- Volunteers
- 654 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Colorectal Liver Metastases (CRCLM), Unresectable Colorectal Liver Metastases
Yttrium-90 Radioembolization Neoadjuvant Therapy With Immune Marker Profiling and Dosimetry for Potentially Resectable Patients With Colorectal Liver Metastases
This is a observational, prospective, single arm, proof of concept study to assess safety, feasibility, and potential efficacy of combining Yttrium-90 transarterial radioembolization(TARE) with standard systemic therapy in…
- Trial name
- YRENE (NCT07406126)
- Testing
- Yttrium-90 Radioembolization with standard systemic therapy
- Where
- 5 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fernando Gómez Muñoz
Colorectal Cancer
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
The standard treatment for locally advanced rectal cancer involves chemotherapy and radiation, known as 5FUCMT, (the chemotherapy drugs 5-fluorouracil/capecitabine and radiation therapy) prior to surgery.
- Trial name
- NCT01515787
- Testing
- FOLFOX (chemotherapy), 5 FUCMT (chemoradiation), surgery
- Where
- 1,073 sites in United States, Canada and 2 more
- Volunteers
- 1,194 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colonic Cancer, Metastasis
Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer
Oral curcumin (complex C3, Sabinsa Corp, Utah) will be given to patients with inoperable colorectal metastases who will be commencing standard care oxaliplatin-based (FOLFOX) chemotherapy for up to 12 cycles(approximately 6…
- Trial name
- CUFOX (NCT01490996)
- Testing
- Oral complex C3 curcumin + chemotherapy, Chemotherapy only
- Where
- United Kingdom
- Volunteers
- 41 people
- Sponsor
- University of Leicester
Colorectal Adenocarcinoma, RAS Wild Type
5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab
This randomized trial studies how well panitumumab, leucovorin calcium, and fluorouracil after combination chemotherapy and panitumumab induction work in treating patients with RAS wild type colorectal cancer that has spread from…
- Conditions
- Colorectal Adenocarcinoma, RAS Wild Type, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7
- Trial name
- NCT03300609
- Testing
- Panitumumab, Oxaliplatin, Leucovorin Calcium
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Southern California
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum
A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer
Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Conditions
- Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00060411
- Testing
- erlotinib hydrochloride, fluorouracil, leucovorin calcium
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Cholangiocarcinoma, Intrahepatic
Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma
Oncolytic viruses can selectively replicate in and destroy tumor cells. Recent studies indicate that recombinant human adenovirus type 5 (H101), which is the first approved oncolytic virus drug in the world, shows anti-tumor…
- Trial name
- NCT05124002
- Testing
- Recombinant Human Adenovirus Type 5, HAIC of FOLFOX
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Unresectable or Metastatic Colorectal Cancer
FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer
To observe and evaluate the efficacy and safety of FOLFOX/FOLFIRI± target-directed regimen containing Levofolinic Acid (Zuoyu ®) in first-line treatment of unresectable or metastatic colorectal cancer
- Trial name
- NCT05797883
- Testing
- FOLFOX/FOLFIRI
- Where
- China
- Volunteers
- 30 people
- Sponsor
- China Medical University, China
Hepatocellular Carcinoma
HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC
Zoledronic acid was initially used for bone metastases in various malignancies. However, it is unknown whether hepatic arterial infusion chemotherapy combined with zoledronic acid can improve overall survival of unresectable…
- Trial name
- NCT05866172
- Testing
- HAIC, Zoledronic acid
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Sun Yat-sen University
Colorectal Neoplasm, Colorectal Cancer
NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer
The main clinical hypothesis is that compared to radio-chemotherapy for low and mid rectal tumors or surgery for high rectal tumors neoadjuvant chemotherapy reduces the rate of distant relapse without increasing the rate of local…
- Conditions
- Colorectal Neoplasm, Colorectal Cancer, Rectal Neoplasms, Chemotherapy Effect
- Trial name
- NEOLAR (NCT03280407)
- Testing
- Capecitabine, FOLFOX regimen (oxaliplatin/leucovorin/5FU), CAPOX (oxaliplatin/capecitabine)
- Where
- Denmark
- Volunteers
- 124 people
- Sponsor
- Zealand University Hospital
Hepatocellular Carcinoma
HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin plus fluorouracil/leucovorin compared with HAIC of oxaliplatin alone in patients with hepatocellular…
- Trial name
- NCT03468231
- Testing
- Sorafenib, HAIC of FOLFOX, HAIC of OXA
- Where
- 7 sites in China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
PURPOSE: This randomized phase III trial is studying giving oxaliplatin, leucovorin calcium, and fluorouracil together to compare how well they work when given together with or without celecoxib in treating patients with stage…
- Trial name
- NCT01150045
- Testing
- celecoxib, 5-fluorouracil, oxaliplatin
- Where
- 842 sites in United States, Canada and 1 more
- Volunteers
- 2,527 people
- Sponsor
- Alliance for Clinical Trials in Oncology